Antibacterial activity of clarithromycin loaded PLGA nanoparticles

Area of Science:

• Pharmaceutical Sciences
• Materials Science
• Microbiology

Background:

• Novel drug delivery systems, particularly nanoparticles (NPs), offer enhanced therapeutic efficacy.
• Clarithromycin (CLR) is a vital broad-spectrum macrolide antibiotic for various bacterial infections.
• Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible polymer frequently used in drug delivery systems.

Purpose of the Study:

• To prepare and characterize clarithromycin-loaded poly(lactic-co-glycolic acid) nanoparticles (CLR NPs).
• To evaluate the enhanced in vitro antibacterial activity of CLR NPs compared to free clarithromycin.

Main Methods:

• Modified quasi-emulsion solvent diffusion (MQESD) method for nanoparticle preparation.
• Agar well diffusion assay to assess antibacterial activity against Escherichia coli, Haemophilus influenzae, Salmonella typhi, Staphylococcus aureus, and Streptococcus pneumoniae.

Main Results:

• CLR NPs demonstrated significantly increased inhibition zone diameters against all tested bacteria compared to untreated CLR.
• The enhancement in antibacterial activity was particularly pronounced against Staphylococcus aureus.
• Improved efficacy is attributed to nanoparticle properties like altered surface characteristics and enhanced drug uptake.

Conclusions:

• Clarithromycin-loaded PLGA nanoparticles represent an effective drug delivery system for enhancing antibiotic potency.
• These findings suggest CLR NPs hold potential for improved treatment of bacterial infections, especially those caused by S. aureus.
• Nanoparticle formulation can overcome limitations of conventional drug delivery, leading to better therapeutic outcomes.